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The mature human immunodeficiency virus type 1
protease rapidly folds into an enzymatically active sta-
ble dimer, exhibiting an intricate interplay between
structure formation and dimerization. We now show by
NMR and sedimentation equilibrium studies that a mu-
tant protease containing the R87K substitution (PRR87K)
within the highly conserved Gly86-Arg87-Asn88 sequence
forms a monomer with a fold similar to a single subunit
of the dimer. However, binding of the inhibitor DMP323
to PRR87K produces a stable dimer complex. Based on
the crystal structure and our NMR results, we postulate
that loss of specific interactions involving the side chain
of Arg87 destabilizes PRR87K by perturbing the inner
C-terminal -sheet (residues 96–99 from each monomer),
a region that is sandwiched between the two -strands
formed by the N-terminal residues (residues 1–4) in the
mature protease. We systematically examined the fold-
ing, dimerization, and catalytic activities of mutant pro-
teases comprising deletions of either one of the terminal
regions (residues 1–4 or 96–99) or both. Although both
N- and C-terminal -strands were found to contribute to
dimer stability, our results indicate that the inner C-
terminal strands are absolutely essential for dimer for-
mation. Knowledge of the monomer fold and regions
critical for dimerization may aid in the rational design
of novel inhibitors of the protease to overcome the prob-
lem of drug resistance.
Human immunodeficiency virus type 1 (HIV-1)1 is a 99-
residue aspartic acid protease and is active as a homodimer.
The interface of the free protease dimer is stabilized through
interactions between the two subunits at the active site and at
the termini (1, 2). The protease catalyzes its own release from
the Gag-Pol polyprotein in addition to the maturation of the
virally encoded structural proteins and replication enzymes
required for the assembly and production of viable virions (3).
Thus, the protease has served as one of the primary targets for
the development of drugs against AIDS. Structure-based de-
sign of drugs targeted against the wild-type mature protease
has aided in the development of several potent inhibitors that
are specific for binding to the active site (4). Although several of
these drugs are in clinical use and have curtailed the progres-
sion of the disease, the effectiveness of long-term treatment has
been restricted due to naturally selected protease variants
exhibiting lower affinity for the drugs than the wild-type en-
zyme. Various drug-resistant mutants of the protease have
been identified (5). Different resistance mechanisms based on
the observed structural changes in drug-resistant mutants
have been proposed. In general, the mutants modulate struc-
ture and interactions within the active site as well as inter- and
intrasubunit flexibility (6–8).
Because of the difficulty in designing active-site inhibitors
that avoid the problem of drug resistance, the target region for
drug development has been extended to areas in which no
drug-selected mutations have occurred to date (9, 10). These
regions are generally well conserved and critical to the struc-
ture and function of the protease. Sequence alignment of ret-
roviral proteases shows that the most conserved regions corre-
spond to (i) the active site (amino acids 22–34), (ii) the flap
(amino acids 47–52), and (iii) amino acids 84–94 encompassing
a single -helix (11). Although the active-site triad Asp25-
Thr26-Gly27 is common to all aspartic acid proteases, Gly86-
Arg87-(Asn/Asp88) in the -helix is unique to retroviral pro-
teases (12), and its structural significance is not fully
understood. We showed in earlier studies that a conservative
substitution of Arg87 with Lys results in total loss of proteolytic
activity, although binding to pepstatin A, a well known inhib-
itor of aspartic acid proteases, is not curtailed (13). However,
detailed structural investigations of this mutant were not fea-
sible earlier due to lack of an expression system for producing
large amounts of this protein and limited knowledge of opti-
mized conditions for studies by solution NMR.
Although NMR solution studies of free wild-type PR are not
possible due to rapid self-degradation, they have become feasi-
ble using a stabilized protease variant that carries the follow-
ing five mutations, Q7K, L33I, and L63I to restrict self-degra-
dation and C65A and C95A to avoid cysteine-thiol oxidation
(14). This protease variant (termed PR herein) exhibits essen-
tially the same kinetic parameters and stability as the wild-
type protein (15).
To investigate the importance of Arg87 for protease structure
and function, we introduced the R87K mutation into PR
(termed PRR87K). NMR and sedimentation equilibrium experi-
ments show that PRR87K forms a semi-stable folded monomer
in solution. Our results further suggest that the R87K muta-
tion exerts an effect on dimer formation of the protease, inter-
fering with the correct positioning of the C-terminal -strands
(residues 96–99) at the interface. The contribution of the ter-
minal -sheet to folding and dimer formation was systemati-
cally analyzed using proteins that lack either the N-terminal
(PR-(5–99)) or C-terminal (PR-(1–95)) 4 residues or both (PR-
* This work was supported by the Intramural AIDS Targeted Anti-
Viral Program of the Office of the Director of the National Institutes of
Health. The costs of publication of this article were defrayed in part by
the payment of page charges. This article must therefore be hereby
marked “advertisement” in accordance with 18 U.S.C. Section 1734
solely to indicate this fact.
** To whom correspondence should be addressed: Laboratory of
Chemical Physics, Rm. 411, Bldg. 5, NIDDK, NIH, Bethesda, MD
20892. Tel.: 301-594-3122; Fax: 301-480-4001; E-mail: jmlouis@helix.
nih.gov.
1 The abbreviations used are: HIV-1, human immunodeficiency virus
type 1; PR, HIV-1 protease; Nle, norleucine; HSQC, heteronuclear sin-
gle quantum coherence spectroscopy; NOE, nuclear Overhauser effect.
THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 276, No. 52, Issue of December 28, pp. 49110–49116, 2001
Printed in U.S.A.
This paper is available on line at http://www.jbc.org49110









(5–95)). The enzymatic activities of these mutant proteins are
reported and compared with those of PR and wild-type PR.
EXPERIMENTAL PROCEDURES
Sample Preparation—The R87K mutation and a stop codon were
introduced into the PR template (which encodes the five mutations
Q7K, L33I, L63I, C67A, and C95A) (15) to generate the PRR87K and
PR-(1–95) constructs, respectively, using the QuickChange mutagene-
sis protocol (Stratagene, La Jolla, CA). The PR-(5–99) construct (15)
was used to generate the PR-(5–95) clone using the same mutagenesis
protocol and the primers used for creating PR-(1–95). The mutant
proteases used in the study are listed in Fig. 1.
PR and its derived mutants were expressed in Escherichia coli
BL21(DE3) in LB or minimal medium containing [15N]ammonium chlo-
ride and/or [13C]glucose as the sole nitrogen and carbon sources at 37 °C
(16). All proteins were isolated using a common protocol, which com-
prises isolation of inclusion bodies followed by fractionation of the
protease by size-exclusion and reversed-phase high-pressure liquid
chromatography. Proteins (2–3 mg) at a concentration of 0.33 mg/ml
in 35% acetonitrile/water containing 0.05% trifluoroacetic acid were
folded by dialysis against 2 liters of 30 mM formic acid (pH 2.8) for 1.5 h,
followed by dilution of the protein with a 5-fold excess of 10 mM acetate
buffer (pH 6.0) to shift the pH to 4, either with or without a saturating
amount of DMP323 (Ki  10 nM) (17), and dialysis against 4 liters of 20
mM sodium phosphate (pH 5.8) for another 1.5 h. Proteins were concen-
trated to achieve a final concentration of0.4 mM for NMR analysis and
to a concentration of 0.05 mM for sedimentation equilibrium studies
and enzyme kinetics. Concentrations of PR and its mutants are ex-
pressed for a dimer, unless otherwise noted. Although the amount of
DMP323 added is equivalent to a 5 mM final concentration, the actual
concentration is unknown due to the poor solubility of DMP323 in
aqueous buffers.
Protease Assays—Protease assays were initiated by mixing 5 l of
freshly folded PRR87K (59 M) or PR-(1–95) (52 M), 10 l of 2 incu-
bation buffer (200 mM potassium phosphate buffer (pH 5.6) and 0.2 M
(buffer A) or 2 M (buffer B) NaCl), and 5 l of 0.2 mM substrate.
PR-(5–99) was assayed in buffer B at a final enzyme concentration of 1
M. The reaction mixture was incubated at 37 °C for 1 h, and the
reaction was terminated by the addition of guanidine HCl to a final
concentration of 6 M. The solution was acidified with trifluoroacetic
acid, and an aliquot was injected onto a Nova-Pak C18 reversed-phase
chromatography column (3.9  150 mm; Waters Associates, Inc., Mil-
ford, MD) using an automatic injector. Substrates and the cleavage
products were separated using a water/acetonitrile gradient (0–100%)
in the presence of 0.05% trifluoroacetic acid. PR-(5–99) was assayed
using the substrates listed in Table I. Substrates corresponding to the
cleavage sites CA/p2, p6pol/PR, PR/RT, RT/IN (for the oligopeptide
sequences, see Table I), MA/CA (VSQNY2PIVQ), and p2/NC
(TATIM2MQRG) were used to assay PRR87K and PR-(1–95).
The mutant enzymes PRR87K and PR-(1–95) were also assayed using
a spectrophotometric substrate, Lys-Ala-Arg-Val-Nle-(4-nitrophenyl-
alanine)-Glu-Ala-Nle-NH2, in 100 mM sodium acetate (pH 5.0) at 25 °C
in a final concentration of 0.96 M PR-(1–95) or 2.9 M PRR87K and 460
M substrate as described previously (15). The kinetic parameters for
PR-(5–99)-catalyzed hydrolysis of the identical spectrophotometric sub-
strate were reported previously (15).
Sedimentation Equilibrium Analyses—Sedimentation equilibrium
experiments were carried out at 20 °C using four different rotor speeds
(10,000, 12,000, 14,000, and 30,000 rpm) on a Beckman Optima XL-A
analytical ultracentrifuge. Data were acquired as an average of eight
absorbance measurements at a nominal wavelength of 280 nm and a
radial spacing of 0.001 cm. Equilibrium was achieved within 24 h.
Protein samples (PR, PR-(1–95), PR-(5–99), and PRR87K), in the absence
or presence of an 10-fold excess of the potent inhibitor DMP323 over
the enzyme concentration, were prepared in 20 mM sodium phosphate
(pH 5.8) and loaded into the ultracentrifuge cells at nominal loading
concentrations of 0.80 A280 units.
Data were analyzed in terms of a single ideal solute by fitting to the
following equation: Ar  Ao,rexp(HM(r
2  r2o))  E, where Ao,r is the
absorbance of the solute at a reference radius (ro) and Ar is the absorb-
ance at a given radial position (r). H represents 2/2RT, where  is the
angular speed in radians/s, R is the gas constant, and T is the absolute
temperature. The value of M represents the experimentally returned
value of the buoyant molecular mass, M(1  v). E is a small base-line
correction determined experimentally at 30,000 rpm.
Values for the experimental molecular mass were determined using
tabulated values for the density (), whereas the partial specific volume
(v) was calculated based on the amino acid composition using the
consensus data for the partial specific molar volumes of amino acids
published by Perkins (18). This value was corrected to account for the
isotopic composition of the proteins studied. For PRR87K, PR-(1–95), and
PR-(5–99), uniformly 15N-labeled proteins were used; and for PR, 10%
13C-labeled and uniformly 15N-labeled proteins were used.
NMR Experiments—NMR experiments were carried out using pro-
tein concentrations of 0.4–0.5 mM in 20 mM phosphate buffer in 95%
H2O and 5% D2O and a sample volume of 280 l in a 5-mm Shigemi
tube (Shigemi, Inc., Allison Park, PA). NMR spectra were acquired on a
DMX500 spectrometer (Bruker Instruments, Billerica, MA). All exper-
iments were conducted at 20 °C unless noted otherwise. Data were
processed and analyzed using nmrPipe, nmrDraw, and PIPP software
(19, 20).
1H-15N HSQC spectra of PRR87K, PR-(1–95), and PR-(5–99) were
recorded at pH 5.8 with and without DMP323. Backbone signal assign-
ments of PR and PRR87K, in the presence and absence of DMP323, were
made using HNCA and CBCA(CO)NH experiments (21, 22). Three-
dimensional experiments for the assignment of free PRR87K were car-
ried out at pH 4.5 to slow aggregation of the sample. 15N longitudinal
relaxation times (T1),
15N transverse relaxation times (T2), and
15N-{H}
NOEs for free PRR87K were measured in an interleaved manner (23)
with repetition delays of 2 s for T1 and T2 determination and 3 s for
NOE determination. Relaxation delays were 0.0016, 0.16, 0.32, 0.48,
0.64, 0.8, and 0.96 s for T1 measurements and 6, 12, 24, 42, 60, 84, and
96 ms for T2 measurements. Diffusion experiments were carried out in
D2O phosphate buffer using bipolar gradient pulses in a longitudinal-
eddy-current delay pulse sequence (24) for PRR87K, with and without
DMP323, and for ubiquitin.
RESULTS AND DISCUSSION
Structural Features of PRR87K Derived from Chemical
Shifts—PR folds from a denatured state into an enzymatically
active stable dimer similar to wild-type PR when dialyzed from
pH 2.8 to 4.2–5.8. The 1H-15N correlation spectrum recorded on
a freshly prepared sample of PRR87K, folded under identical
conditions as PR, displayed a set of well dispersed signals,
indicating a folded conformation of the protein (Fig. 2a). How-
ever, in contrast with PR, PRR87K aggregated at a concentra-
tion of 0.4 mM, resulting in an 50% loss in signal intensity
within 1 day. The addition of the potent inhibitor DMP323 to
PRR87K resulted in two sets of signals (Fig. 2b), with the minor
set belonging to free PRR87K. The C- chemical shifts of the
major set for PRR87K in the presence of DMP323 (Fig. 3b) were
nearly identical to those of the PR-DMP323 complex, suggest-
ing that both dimer complexes exhibit very similar structures.
Even in the absence of DMP323, the overall backbone C-
chemical shifts of PRR87K residues were similar to those of PR
FIG. 1. Amino acid sequences of mature HIV-1 protease constructs. Red and gray indicate the two highly conserved regions, the active-site
(DTG) and C-terminal (GR(N/D)) triads, in retroviral proteases. All of the constructs bear five mutations: three mutations (Q7K, L33I, and L63I)
to restrict degradation and two mutations (C65A and C95A) to avoid Cys-thiol oxidation. The N- and C-terminal residues involved in forming the
interface -sheet (see Fig. 4b) are highlighted in yellow. wt-PR, wild-type PR.
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(Fig. 3a). However, unlike the DMP323-bound forms of PR and
PRR87K, significant differences in the chemical shifts of the free
forms of PR and PRR87K were noted for residues at the dimer
interface, i.e. near the active site (residues 24–29) and the N-
and C-terminal regions (residues 1–10 and 90–99, respective-
ly). In particular, the peaks for Ile3, Gln92, Ile93, Gly94, and
Ala95 that significantly shifted in the dimer due to intermono-
mer and not DMP323 interaction were not observed in the
corresponding positions in the free PRR87K spectrum (Figs. 2a
and 3a). Since Arg87 is located far from the N- and C-terminal
residues (15 Å), the observed chemical shift differences be-
tween PRR87K and PR corresponding to the terminal residues
were not caused by changes in the local magnetic environment
upon mutation, but rather by the structural changes of the
protein. Overall, the similarity in chemical shifts for uncom-
plexed free PRR87K and PR, except for the dimer interface
regions, suggests that the fold of PRR87K is similar to that of
PR.
PRR87K Forms a Semi-stable Monomer—The dynamics of
PRR87K in the absence of DMP323 were probed by carrying out
15N relaxation experiments (see Fig. 5). For the most part, the
T1 and T2 values of PRR87K were quite uniform (0.5–0.6 s and
90–100 ms, respectively), although different from those of PR
(0.7–0.9 s and 60–70 ms, respectively).2 The rotational corre-
lation time estimated from the T1/T2 ratios was 7.5 ns. This
2 Freedburg, D. I., Ishima, R., Jocob, J., Wang, Y.-X., Kustanovich, I.,
Louis, J. M., and Torchia, D. A. (2001) Protein Sci., in press.
TABLE I
Kinetic parameters for PR and PR-(5–99) protease-catalyzed hydrolysis of Gag-Pol substrates
Assays were performed in 250 mM sodium phosphate (pH 5.6) and 2 M NaCl at 37 °C in a final enzyme concentration of 0.01–0.1 M PR and 1
M PR-(5–99). ND, not determined. MA, CA, NC, RT, and IN denote matrix, capsid, nucleocapsid, reverse transcriptase, and integrase proteins,
respectively.
Cleavage site Substrate Enzyme Km kcat kcat/Km
mM s1 mM1 s1
PR 0.021  0.004 0.89  0.03 42.4
CA/p2 KARVL2AEAMS PR-(5–99) 0.192  0.02 0.11  0.02 0.6
PR-(5–99) 0.01 0.09 ND
p6pol/PR VSFNF2PQITL PR-(5–99) 0.02 0.002 ND
PR 0.044  0.008 1.72  0.08 39.1
PR/RT CTLNF2PISP PR-(5–99) 0.087  0.014 0.05  0.01 0.6
PR 0.032  0.006 0.41  0.02 12.8
In RT AETF2YVDGAA PR-(5–99) 0.041  0.01 0.008  0.001 0.2
PR 0.016  0.005 1.20  0.06 75.0
RT/IN IRKIL2FLDG PR-(5–99) 0.046  0.006 0.08  0.01 1.7
FIG. 2. Amide 1H-15N HSQC spectra
of freshly prepared PRR87K (a) and
PRR87K in the presence of DMP323 (b)
measured at 20 °C. Boxes in a and b
delineate the locations of peaks that ex-
hibited significant changes due to dimer
formation. Peaks of Gly68 for the dimer
and monomer forms of PRR87K are labeled
G68D and G68M, respectively.
FIG. 3. Differences in backbone C-
chemical shifts between PR and
PRR87K in the absence (a) and pres-
ence (b) of DMP323 together with the
secondary structure of PR. The single
-helix and the -strands are depicted as
a coil and white arrows, respectively. Res-
idue 51, whose C- was not assigned due
to broadening of the signal in PRR87K, is
indicated.
Folded Monomer of HIV-1 Protease49112









correlation time is significantly smaller than that observed for
PR (12.9 ns) under similar conditions (0.3 mM protein in 20 mM
sodium phosphate (pH 5.8) at 20 °C) (14) despite the noted
tendency of PRR87K to aggregate. Using an NMR approach (24),
we determined the relative translational diffusion coefficient of
PRR87K to be 1.5  10
10 m2/s. This value lies between those
measured for the PR-DMP323 complex (1.0  1010 m2/s) and
ubiquitin (2.1 1010 m2/s), proteins with molecular masses of
22 and 8.5 kDa, respectively. This suggests that PRR87K has a
mass close to that expected for the protease monomer (Fig. 4c).
Sedimentation equilibrium data for the PRR87K mutant con-
firmed the monomeric state. The data fit well to a single solute
model with a molecular mass equal to that of the monomer
(Table II). All of the above results together suggest that PRR87K
is a folded monomer in solution. The tendency for the PRR87K
monomer to aggregate at a concentration of 0.5 mM suggests
that it is less stable, unlike dimeric PR, which exhibits a stable
fold and does not aggregate even at 1 mM.
Analysis of the 15N relaxation experiments revealed signifi-
cant motions on the subnanosecond time scale for both N- and
C-terminal residues 2–10 and 93–99, respectively; the elbow
residues 37–42, and the flap residues 48–53 in PRR87K as
shown by the elevated T1 and T2 values and reduced NOE
values (Fig. 5). Although the mobilities of the flap and elbow
regions have been shown for free PR, increased motion of the
termini had not been observed (25, 26). Inspection of a model of
monomeric protease (Fig. 4c) revealed that the areas identified
as mobile correspond to solvent-exposed regions, assuming that
the monomeric structure remains essentially identical to a
single subunit of the dimer.
Analysis of protease crystal structures revealed that the
N-terminal (residues 1–4) and C-terminal (residues 96–99)
residues contribute50% of the dimer interface, critical for PR
stability (1). The four-stranded antiparallel -sheet is orga-
nized such that the two C-terminal -strands are sandwiched
between the two N-terminal -strands at the bottom of the
protease structure (Fig. 4b). The highly conserved Arg87 resi-
due, residing on the sole -helix (residues 87–91), forms a
hydrogen bond with Asp29, a residue that is located near the
active site (Fig. 4d) (27). In PRR87K, chemical shift perturba-
tions and subnanosecond motions detected for the N-terminal
residues of the -helix increased further in the C-terminal
-strand. Taking into account the above NMR results together
with information from crystal structures, we propose that dis-
ruption of the specific interactions involving the Arg87 side
chain could destabilize the terminal -sheet and induce en-
hanced mobility at the dimer interface.
Inhibitor Binding Stabilizes the PRR87K Dimer—As shown
above, inhibitor DMP323 binding could induce dimerization of
PRR87K, although a small fraction of the PRR87K monomer was
still present as evidenced by the HSQC spectrum (Fig. 2b).
Since DMP323 has very poor solubility in aqueous buffers (see
“Experimental Procedures”), complete saturation of PRR87K
with inhibitor could not be achieved. The above result is con-
sistent with the monomer/dimer-DMP323 complex ratio deter-
mined by sedimentation equilibrium studies (Table II). Under
the same conditions of inhibitor saturation, we never observed
free PR, indicating that the affinity of DMP323 for PR has to be
significantly higher. It has been shown that the highly hydro-
phobic DMP323 interacts tightly with the methyl groups of
aliphatic residues that line the substrate-binding pocket (28).
This binding site is composed of residues residing in both
monomeric subunits; thus, binding of DMP323 would favor the
dimer over the monomer structure, i.e. binding induces dimer-
ization. Indeed, DMP323 could be viewed as a staple keeping
the monomers together, the molecular interactions alone of
which are not sufficient for this purpose, as in the case of the
PRR87K mutant. However, substrates are not expected to sta-
bilize the PRR87K dimer to the same extent as DMP323, as the
binding affinity of substrates is much lower than that of
DMP323. This interpretation is consistent with our observation
that a substrate analog inhibitor of PR (Arg-Val-Leu-®-Phe-
Glu-Ala-Nle-NH2, where ® denotes a reduced peptide bond; Ki
 89 nM) (15) and substrate (Lys-Ala-Arg-Val-Nle-(4-nitrophe-
nylalanine)-Glu-Ala-Nle-NH2; Km  177 M) (15) give spectra
similar to those shown in Fig. 2a (data not shown), implying
that substrates do not stabilize the dimeric structure of
PRR87K.
Loss of the Catalytic Activity of PRR87K—The fact that
PRR87K is a monomer is consistent with the observed loss of its
catalytic activity. PRR87K was assayed against substrates rep-
resenting cleavage sites between the major Gag and Gag-Pol
domains. No sign of cleavage was observed using PRR87K, ex-
cept for the MA/CA and p6pol/PR substrates, for which very low
levels of cleavage were observed. Based on the specific activity
values, PRR87K was calculated to have 6700- and 1800-fold
lower activity than PR in buffers A and B, respectively (Table
III). PRR87K exhibited a 4600-fold lower specific activity com-
pared with PR as measured by the spectrophotometric assay.
Influence of Terminal Deletions on Folding, Dimerization,
and Catalytic Activity—The role of the interfacial -sheet com-
prising the N- and C-terminal strands in protease structure
and function was examined using deletions mutants of either
one of the terminal -strands (residues 1–4 or 96–99) or both.
FIG. 4. Ribbon representations of the structure of mature
HIV-1 protease (a), the terminal -sheet interface (b), regions
that exhibit pico/nanosecond time scale motions (NOE < 0.5) in
the PRR87K monomer (shown in green) (c), and details of the
structure surrounding Arg87 (d). In a and b, the terminal -strands
(residues 1–4 and 96–99) of one subunit are colored in green and the
other cyan. In d, the side chains of Asp29 and Arg87 are depicted in red,
and the side chains of the active-site Asp25 residues are colored in the
same color as the corresponding subunit backbone. The region (residues
87–95) encompassing the -helix is shown in purple, and the adjoining
C-terminal -strand is shown in cyan in d. The structures were drawn
using the coordinates of Protein Data Bank code 1A8K (www.rcsv.org).
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The truncated proteins PR-(1–95), PR-(5–99), and PR-(5–95)
(Fig. 2) were purified and refolded essentially as described for
PR and PRR87K (see “Experimental Procedures”). At low con-
centration (50 M), PR-(1–95) and PR-(5–99) were soluble in
the pH range of 4–5.8, similar to PR and PRR87K. However, at
higher concentrations, in either the absence or presence of
DMP323, PR-(5–95) displayed severe aggregation, precluding
any structural analysis by NMR. Apparently at least one of the
terminal -strands is required to maintain structural stability
and reasonable solubility of the protease.
Although the three mutations Q7K, L33I, and L63I in the
protease reduce self-degradation at pH 5.0, cleavage still oc-
curs, albeit at a much slower rate compared with wild-type PR,
permitting NMR studies (26, 29). Degradation of PR can be
further reduced by conducting the experiments at a slightly
higher pH and lower temperature, such as 20 mM sodium
phosphate (pH 5.8) and 20 °C (14). The truncated proteins
PR-(1–95) and PR-(5–99) behaved differently under these con-
ditions. PR-(1–95) did not show any degradation products (sim-
ilar to PRR87K), whereas PR-(5–99) clearly was proteolyzed, as
evidenced by the appearance of additional resonances in the
1H-15N HSQC spectrum (Fig. 6a, dotted enclosed area). The
degradation products of PR-(5–99) most likely arise from cleav-
age at the dipeptide sequences Ile33-Glu34 and Ile63-Ile64 (29).
Based on these observations, we suggest that PR-(5–99) forms
an active dimeric protein that is capable of autoproteolysis at
higher protein concentrations. The kinetic parameters for PR-
and PR-(5–99)-catalyzed hydrolysis of substrates under identi-
cal conditions are summarized in Table I. The catalytic activity
of PR is similar to that of wild-type PR (30). The low kcat/Km
observed for PR-(5–99) using five different substrates suggests
that only a small fraction of the protein contributes to the
observed activity. The present results are consistent with our
earlier study, in which we observed an 50-fold lower kcat/Km
for PR-(5–99) compared with PR assayed using a spectropho-
tometric substrate (15). PR-(1–95) did not exhibit detectable
cleavage of any of the substrates tested.
The 1H-15N HSQC spectra of freshly prepared PR-(1–95) and
PR-(5–99) recorded in the absence of DMP323 were similar to
that of the PRR87K monomer spectrum. Peaks that were unique
to the dimer were absent in both cases (Fig. 6, dotted boxes).
The addition of excess DMP323 to the proteins shifted the
equilibrium for PR-(5–99) to a dimer (similar to the spectrum
shown in Ref. 15), but not that for PR-(1–95), which still ex-
hibited the spectrum of a monomer (similar to Fig. 6b). The
molecular masses estimated for PR-(1–95) and PR-(5–99) by
sedimentation equilibrium analysis and the consensus derived
from both NMR and sedimentation equilibrium analyses re-
garding the observed folded dimer and monomer forms of the
different constructs used in this study are shown in Table II.
In earlier studies, we had shown that after 2 days at a
concentration of 1.2 mM, PR-(5–99) exhibited a spectrum typ-
ical of a random-coil polypeptide; in addition, weak intensity
dispersed signals corresponding to a folded conformation were
also observed (15). We reexamined freshly prepared samples of
PR-(1–95) and PR-(5–99) at a concentration of 1 mM to deter-
mine the effect of protein concentration on dimerization. The
spectrum of PR-(1–95) essentially remained that of a monomer
(Fig. 6b), whereas the spectrum of PR-(5–99) showed a signif-
icant fraction of the signals corresponding to a dimer. The
TABLE II
Estimated molecular masses and major folded species of HIV-1 protease constructs
Constructa Inhibitor DMP323b




PR  20,370  240 10,906.6 1.87  0.02 Dimer
 21,980  560 1.96  0.01 Dimer-DMP323 complex
PRR87K  10,620  530 10,827.9 0.98  0.05 Monomer
d
 17,420  940e 1.57  0.09 Monomerd  dimer-DMP323 complex
PR-(1–95)  10,440  370 10,377.4 1.01  0.04 Monomerd
 11,790  1150e 1.13  0.11 Monomerd
PR-(5–99)  10,860  120 10,471.5 1.04  0.01 Monomerd  dimer
 20,080  690 1.87  0.06 Dimer-DMP323 complex
a PR-(5–95) precipitated completely with no observable NMR signal.
b Calculated molecular mass of DMP323  567 Da.
c Data were determined by NMR and sedimentation equilibrium studies.
d These samples have a tendency to aggregate at 0.4 mM (as a dimer).
e Data were forced to fit to a single exponential decay function. To prevent underestimate of the errors, the largest fitting errors among the data
measured at various rotor speeds are shown for these two cases. Otherwise, errors are standard deviations of the data measured at various rotor
speeds and are compatible with or slightly larger than the fitting error.
FIG. 5. 15N T2 (a),
15N T1 (b), and
15N{H} NOE (c) values of
backbone amides of PRR87K. The secondary structure of PR is de-
picted at the top.
TABLE III
Comparison of specific activities of PR and PRR87K
Assays were performed in 100 mM potassium phosphate (pH 5.6)
either in 0.1 M (buffer A) or 1 M (buffer B) NaCl at a final concentration
of 200 M p6pol/PR substrate and 0.02 M PR or 15 M PRR87K.
Enzyme
Specific activity
Buffer A Buffer B
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propensity of PR-(5–99) to dimerize with increasing protein
concentration was similar to that observed for an analogous
deletion construct of the Rous sarcoma virus protease (31).
Three major conclusions can be drawn from the analysis of
the protease constructs that have either one or both of the
terminal -stands deleted. 1) The presence of at least one of the
terminal -strands (residues 1–4 or 96–99) is required for
monomer folding; 2) both terminal strands contribute to dimer
stability; and 3) the interaction between the C-terminal
-strand residues is pivotal for dimerization.
Relationship between Protease Dimer Stability and Func-
tion—In HIV, a single copy of the protease is synthesized as
part of the Gag-Pol polyprotein, flanked by the p6pol and re-
verse transcriptase domains at the N and C termini, respec-
tively. Previous studies indicated that the protease precursor is
mainly in an unfolded form (15). Transient dimer formation
leads to intramolecular autocatalytic cleavage first at the N
terminus of the protease (p6pol/PR site) concomitant with stable
structure formation and the appearance of enzymatic activity
(15, 32, 33). Subsequent cleavage at the C terminus (PR/RT
site) of the protease occurs via an intermolecular process (34).
Our present results indicate that the -sheet formed by the
central C-terminal -strands of the four-stranded -sheet con-
tributes critically to the stability of the transient dimeric struc-
ture of the protease precursor such that the flexible N-terminal
cleavage site sequence (p6pol/PR) is accessible for intramolecu-
lar cleavage. Binding of inhibitor or possibly substrate to the
active site promotes dimer formation and thereby could com-
pensate for the loss of dimer stability, due to displacement of
the outer -strands (residues 1–4). Similarly, binding of the
N-terminal polypeptide comprising the p6pol/PR cleavage site
to the active site may also contribute to the stability of the
transient dimer formation of the precursor, leading to the hy-
drolysis of the scissile peptide bond and formation of the stable
dimeric structure.
The highly conserved Arg87 residue in the conserved triad
Gly86-Arg87-(Asn/Asp88) of retroviral proteases plays a crucial
role in the stability of the dimer. Loss of specific interactions
involving Arg87, e.g. the hydrogen bond with Asp29, results in
the destabilization of the dimer interfaces, particularly be-
tween the C-terminal -stands as discussed above. The crystal
structures of proteases of related viruses such as HIV-2, equine
infectious anemia virus, feline immunodeficiency virus, Rous
sarcoma virus, and simian immunodeficiency virus also dem-
onstrate close proximity between the side chains of Arg87 and
Asp29. It will be important to investigate whether substitution
of the conserved Arg87 residue in these related retroviral pro-
teases also destabilizes the corresponding dimer.
Our results presented here reveal certain critical regions
essential to the structure, stability, and catalytic activity of the
mature HIV-1 protease. As pointed out in the Introduction,
anti-HIV drugs based on active-site inhibitors contribute to the
emergence of drug-resistant strains, a major problem in cur-
rent treatment of AIDS. Based on our results, it may be possi-
ble and desirable to devise newer strategies for the rationale
design of drugs targeting the dimer interface. Two critical
interactions can be disrupted: 1) the inner two C-terminal
-strands and 2) the pivotal interaction between the Arg87 and
Asp29 side chains. On the other hand, the protease monomer
may aid in the screening of novel compounds that are specific
for binding to the exposed interface.
Acknowledgments—We thank F. Delaglio and D. Garrett for data
processing software, I. Neshiwat for expert technical assistance, and
DuPont Pharmaceuticals for DMP323. We are grateful to S. Oroszlan
for many thoughtful and inspiring discussions.
REFERENCES
1. Weber, I. T. (1990) J. Biol. Chem. 265, 10492–10496
2. Strisovsky, K., Tessmer, U., Langner, J., Konvalinka, J., and Krausslich, H. G.
(2000) Protein Sci. 9, 1631–1641
3. Oroszlan, S., and Luftig, R. B. (1990) Curr. Top. Microbiol. Immunol. 157,
153–185
4. Erickson, J. W., and Burt, S. K. (1996) Annu. Rev. Pharmacol. Toxicol. 36,
545–571
5. Parikh, U., Hammond, J., Calef, C., Larder, B., Schinazi, R., and Mellors, J. W.
(2000) in The 2000 HIV Sequence Compendium: Mutations in Retroviral
Genes Associated with Drug Resistance, pp. 125–138, Los Alamos, NM
(www.hiv.lanl.gov)
6. Rose, R. B., Craik, C. S., and Stroud, R. M. (1998) Biochemistry 37, 2607–2621
7. Erickson, J. W., Gulnik, S. V., and Markowitz, M. (1999) AIDS 13, S189–S204
8. Mahalingam, B., Louis, J. M., Reed, C. C., Adomat, J. M., Krouse, J., Wang,
Y. F., Harrison, R. W., and Weber, I. T. (1999) Eur. J. Biochem. 263,
238–245
9. Shultz, M. D., and Chmielewski, J. (1999) Bioorg. Med. Chem. Lett. 9,
2431–2436
10. Zutshi, R., and Chmielewski, J. (2000) Bioorg. Med. Chem. Lett. 10, 1901–1903
11. Rao, J. K., Erickson, J. W., and Wlodawer, A. (1991) Biochemistry 30,
4663–4671
12. Pearl, L. H., and Taylor, W. R. (1987) Nature 329, 351–354
13. Louis, J. M., Wondrak, E. M., Copeland, T. D., Smith, C. A., Mora, P. T., and
Oroszlan, S. (1989) Biochem. Biophys. Res. Commun. 159, 87–94
14. Ishima, R., Louis, J. M., and Torchia, D. A. (2001) J. Mol. Biol. 305, 515–521
15. Louis, J. M., Clore, G. M., and Gronenborn, A. M. (1999) Nat. Struct. Biol. 6,
868–875
16. Yamazaki, T., Hinck, A. P., Wang, Y. X., Nicholson, L. K., Torchia, D. A.,
Wingfield, P., Stahl, S. J., Kaufman, J. D., Chang, C. H., Domaille, P. J., and
Lam, P. Y. (1996) Protein Sci. 5, 495–506
17. Lam, P. Y., Ru, Y., Jadhav, P. K., Aldrich, P. E., DeLucca, G. V., Eyermann,
C. J., Chang, C. H., Emmett, G., Holler, E. R., Daneker, W. F., Li, L.,
Confalone, P. N., McHugh, R. J., Han, Q., Li, R., Markwalder, J. A., Seitz,
S. P., Sharpe, T. R., Bacheler, L. T., Rayner, M. M., Klabe, R. M., Shum, L.,
FIG. 6. Amide 1H-15N HSQC spectra
of freshly prepared PR-(5–99) (a) and
PR-(1–95) (b) at 20 °C. The locations of
peaks unique to the dimer are boxed (see
legend to Fig. 2). Additional peaks within
the large oval in a result from self-degra-
dation of PR-(5–99).
Folded Monomer of HIV-1 Protease 49115









Winslow, D. L., Kornhauser, D. M., and Hodge, C. N. (1996) J. Med. Chem.
39, 3514–3525
18. Perkins, S. J. (1986) Eur. J. Biochem. 157, 169–180
19. Garrett, D. S., Powers, R., Gronenborn, A. M., and Clore, G. M. (1991) J. Magn.
Reson. 95, 214–220
20. Delaglio, F., Grzesiek, S., Vuister, G. W., Zhu, G., Pfeifer, J., and Bax, A. (1995)
J. Biomol. NMR 6, 277–293
21. Grzesiek, S., and Bax, A. (1992) J. Magn. Reson. 96, 432–440
22. Grzesiek, S., and Bax, A. (1992) J. Am. Chem. Soc. 114, 6291–6293
23. Tjandra, N., Szabo, A., and Bax, A. (1996) J. Am. Chem. Soc. 118, 6986–6991
24. Wu, D. H., Chen, A. D., and Johnson, C. S. (1995) J. Magn. Reson. 115,
260–264
25. Todd, M. J., Semo, N., and Freire, E. (1998) J. Mol. Biol. 283, 475–488
26. Ishima, R., Freedberg, D. I., Wang, Y. X., Louis, J. M., and Torchia, D. A.
(1999) Structure 7, 1047–1055
27. Wlodawer, A., Miller, M., Jaskolski, M., Sathyanarayana, B. K., Baldwin, E.,
Weber, I. T., Selk, L. M., Clawson, L., Schneider, J., and Kent, S. B. (1989)
Science 245, 616–621
28. Ala, P. J., Huston, E. E., Klabe, R. M., McCabe, D. D., Duke, J. L., Rizzo, C. J.,
Korant, B. D., DeLoskey, R. J., Lam, P. Y., Hodge, C. N., and Chang, C. H.
(1997) Biochemistry 36, 1573–1580
29. Mildner, A. M., Rothrock, D. J., Leone, J. W., Bannow, C. A., Lull, J. M.,
Reardon, I. M., Sarcich, J. L., Howe, W. J., Tomich, C. S., Smith, C. W.,
Heinrickson, R. L., and Tomasselli, A. G. (1994) Biochemistry 33,
9405–9413
30. Tozser, J., Blaha, I., Copeland, T. D., Wondrak, E. M., and Oroszlan, S. (1991)
FEBS Let. 281, 77–80
31. Schatz, G. W., Reinking, J., Zippin, J., Nicholson, L. K., and Vogt, V. M. (2000)
J. Virol. 75, 4761–4770
32. Louis, J. M., Nashed, N. T., Parris, K. D., Kimmel, A. R., and Jerina, D. M.
(1994) Proc. Natl. Acad. Sci. U. S. A. 91, 7970–7974
33. Louis, J. M., Wondrak, E. M., Kimmel, A. R., Wingfield, P. T., and Nashed,
N. T. (1999) J. Biol. Chem. 274, 23437–23442
34. Wondrak, E. M., Nashed, N. T., Haber, M. T., Jerina, D. M., and Louis, J. M.
(1996) J. Biol. Chem. 271, 4477–4481
Folded Monomer of HIV-1 Protease49116
 at NCI-Frederick, Scientific Library on February 19, 2007 
w
w
w
.jbc.org
D
ow
nloaded from
 
